Shares of telehealth company Hims & Hers Health Inc. (HIMS) surged as much as 26.35% to an all-time high of $29.68 on Friday, November 11th. The stock closed the trading session at $28.00, capping off a remarkable 213% gain for the year that significantly outperformed the broader market.
The rally was fueled by HIMS' raised full-year revenue forecast and its plans to enter the booming weight loss drug market. Last week, the company increased its 2024 revenue guidance to $1.46-$1.47 billion, up from the previous $1.37-$1.40 billion range. This upward revision came as HIMS announced it will add a generic version of Novo Nordisk's popular diabetes and weight loss medication liraglutide to its platform in 2025.
With soaring demand leading to shortages of brand-name weight loss drugs like Novo's liraglutide and Eli Lilly's blockbuster Mounjaro, HIMS is well-positioned to capitalize on this lucrative market by producing generic alternatives under U.S. regulations. Analysts view the company's entry into the weight loss space as a significant growth opportunity, with TD Cowen raising its HIMS price target to $28 (from $25) on Monday and citing the liraglutide plans as a key driver.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.